
Investors Eye Class Action Against Capricor After Deramiocel Setback
Investors who purchased Capricor Therapeutics securities between December 17, 2025, and July 26, 2026, face a September 28 deadline to seek lead plaintiff status in a federal class action lawsuit. The litigation follows a sharp decline in share price triggered by FDA concerns over the company’s clinical data analysis.






















